CLINICAL_TRIALS
research
· 2025-02-25
Clinical Trial Update: CD123-CD16-NK Cells Immunotherapy for AML [Phase 1]
Summary
Phase 1 clinical trial evaluating CD123-CD16-NK cell immunotherapy for Acute Myeloid Leukemia is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chunji Gao | Conditions: AML (Acute Myelogenous Leukemia), NK Cell | Phase 1 | Status: RECRUITING